Avalo Therapeutics, Inc. (NASDAQ:AVTX) Short Interest Update

Avalo Therapeutics, Inc. (NASDAQ:AVTX) was the recipient of a significant growth in short interest in September. As of September 15th, there was short interest totalling 59,500 shares, a growth of 38.1% from the August 31st total of 43,100 shares. Based on an average daily trading volume, of 16,200 shares, the short-interest ratio is presently 3.7 days. Currently, 0.6% of the shares of the company are sold short.

Institutional Trading of Avalo Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of AVTX. Logos Global Management LP purchased a new stake in Avalo Therapeutics during the 2nd quarter worth approximately $6,722,000. Affinity Asset Advisors LLC raised its stake in Avalo Therapeutics by 350.0% in the 2nd quarter. Affinity Asset Advisors LLC now owns 45,000 shares of the company’s stock valued at $561,000 after purchasing an additional 35,000 shares during the last quarter. Finally, Ikarian Capital LLC purchased a new position in Avalo Therapeutics in the 1st quarter valued at $1,015,000. Hedge funds and other institutional investors own 87.06% of the company’s stock.

Avalo Therapeutics Trading Up 0.5 %

Shares of Avalo Therapeutics stock traded up $0.05 during trading hours on Friday, reaching $9.40. The stock had a trading volume of 13,987 shares, compared to its average volume of 246,103. Avalo Therapeutics has a twelve month low of $3.95 and a twelve month high of $45.10. The stock’s 50 day moving average is $9.62 and its 200 day moving average is $11.22.

Avalo Therapeutics (NASDAQ:AVTX) last posted its quarterly earnings data on Monday, August 12th. The company reported ($14.07) EPS for the quarter, missing analysts’ consensus estimates of ($6.70) by ($7.37). Avalo Therapeutics had a negative net margin of 1,639.50% and a negative return on equity of 306.52%. As a group, equities analysts predict that Avalo Therapeutics will post -7.78 earnings per share for the current fiscal year.

Avalo Therapeutics Company Profile

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.